Literature DB >> 15752680

Prospective evaluation of emerging bacteria in cystic fibrosis.

G Steinkamp1, B Wiedemann, E Rietschel, A Krahl, J Gielen, H Bärmeier, F Ratjen.   

Abstract

BACKGROUND: Bacteria contribute considerably to the progression of lung disease in cystic fibrosis. In this prospective, multi-centre study, we aimed to evaluate the occurrence of emerging bacteria and the physicians' assessments of the clinical importance of these findings.
METHODS: Twelve CF centres (total number of patients: 1419) reported the detection of any Stenotrophomonas maltophilia, Burkholderia cepacia complex, MRSA, Alcaligenes xylosoxidans, Klebsiella species and Mycobacteria during an observation period of 6 months.
RESULTS: 213 specimens with emerging bacteria were reported from 145 different patients. The proportion of patients with emerging bacteria differed between centres (3-38%, mean: 12.6%) and increased with age. The predominant bacterium was S. maltophilia (n=106 positive specimens), followed by Klebsiellae (n=36), B. cepacia complex (n=31), A. xylosoxidans (n=16), Mycobacteria (n=11), MRSA (n=11), and others (n=2). In many instances the same microorganisms had already been reported earlier, indicating intermittent or chronic colonisation. The clinical status was reported to be stable in 70% of patients, and antibiotic treatment was anticipated for 46% of positive specimens. Comparison of clinical data to age matched controls did not reveal any significant differences with regard to pulmonary and nutritional status prior to detection of emerging bacteria.
CONCLUSION: These data suggest a high variability between centres regarding the prevalence of emerging bacteria. Most patients maintained a stable clinical condition during the 6-month study period despite being colonised with emerging bacteria.

Entities:  

Mesh:

Year:  2005        PMID: 15752680     DOI: 10.1016/j.jcf.2004.10.002

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  30 in total

1.  Immunostimulatory properties of the emerging pathogen Stenotrophomonas maltophilia.

Authors:  Valerie J Waters; Marisa I Gómez; Grace Soong; Sunil Amin; Robert K Ernst; Alice Prince
Journal:  Infect Immun       Date:  2007-01-12       Impact factor: 3.441

Review 2.  Clinical significance of microbial infection and adaptation in cystic fibrosis.

Authors:  Alan R Hauser; Manu Jain; Maskit Bar-Meir; Susanna A McColley
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

3.  Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis.

Authors:  Clement L Ren; Michael W Konstan; Ashley Yegin; Lawrence Rasouliyan; Benjamin Trzaskoma; Wayne J Morgan; Warren Regelmann
Journal:  J Cyst Fibros       Date:  2012-03-23       Impact factor: 5.482

4.  Herbaspirillum species: a potential pathogenic bacteria isolated from acute lymphoblastic leukemia patient.

Authors:  Jianguo Chen; Zhaoliang Su; Yingzhao Liu; Siamak Sandoghchian; Dong Zheng; Shengjun Wang; Huaxi Xu
Journal:  Curr Microbiol       Date:  2010-07-13       Impact factor: 2.188

Review 5.  Antibiotic treatment for Stenotrophomonas maltophilia in people with cystic fibrosis.

Authors:  Reshma Amin; Valerie Waters
Journal:  Cochrane Database Syst Rev       Date:  2016-07-14

Review 6.  The changing microbial epidemiology in cystic fibrosis.

Authors:  John J Lipuma
Journal:  Clin Microbiol Rev       Date:  2010-04       Impact factor: 26.132

7.  Biofilm compared to conventional antimicrobial susceptibility of Stenotrophomonas maltophilia Isolates from cystic fibrosis patients.

Authors:  Kitty Wu; Yvonne C W Yau; Larissa Matukas; Valerie Waters
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

Review 8.  Stenotrophomonas maltophilia: an emerging global opportunistic pathogen.

Authors:  Joanna S Brooke
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

9.  Molecular characterization of Achromobacter isolates from cystic fibrosis and non-cystic fibrosis patients in Madrid, Spain.

Authors:  Laura Barrado; Patricia Brañas; M Ángeles Orellana; M Teresa Martínez; Gloria García; Joaquín R Otero; Fernando Chaves
Journal:  J Clin Microbiol       Date:  2013-03-27       Impact factor: 5.948

10.  Adhesion to and biofilm formation on IB3-1 bronchial cells by Stenotrophomonas maltophilia isolates from cystic fibrosis patients.

Authors:  Arianna Pompilio; Valentina Crocetta; Pamela Confalone; Mauro Nicoletti; Andrea Petrucca; Simone Guarnieri; Ersilia Fiscarelli; Vincenzo Savini; Raffaele Piccolomini; Giovanni Di Bonaventura
Journal:  BMC Microbiol       Date:  2010-04-07       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.